Alphamab Oncology logo

Alphamab Oncology(SEHK) 9966

Market CapHK$6.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-48%
5 Year-59%
1 Year-47%
1 Month-14%
HK$6.92
-1.77%
-0.13Today
Alphamab Oncology last closing stock price
MetricPriceDate
Last closeHKD 6.922026-10-14
Alphamab Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.46%HKD 8.092026-10-07
1 month-13.82%HKD 8.032026-09-14
3 month-9.07%HKD 7.612026-07-16
Year to date-29.39%HKD 9.802025-12-31
1 year-47.42%HKD 13.162025-10-14
3 year-29.53%HKD 9.822023-10-13
5 year-59%HKD 16.882021-10-15
Since inception-47.81%HKD 13.502019-12-12

Alphamab Oncology Financials at a Glance

Market Cap

HK$6.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.30B

Net Income (TTM)

CN¥59.05M

EPS (TTM)

-HK$0.20

P/E Ratio

-34.26

Dividend

HK$0.00

Beta (Volatility)

0.00 (Low)

Price

HK$6.92

Volume

1,361,000

Open

HK$7.05

Previous Close

HK$7.05

Daily Range

HK$6.73 - HK$7.06

52-Week Range

HK$6.23 - HK$15.68

Estimated Earnings Date

Mar 30, 2027

9966 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alphamab Oncology

Alphamab Oncology is a clinical-stage biopharmaceutical company focused on developing innovative biological therapies for cancer treatment. The company is advancing a robust pipeline of products, including bispecific monoclonal antibodies and immunotherapies, aimed at addressing significant unmet medical needs in oncology.

Products and Services
  • KN046: A bispecific monoclonal antibody in Phase III trials targeting PD-L1 and CTLA-4 pathways
  • KN026: An anti-HER2 bispecific antibody in Phase II studies for HER2-positive breast cancers
  • KN035: A PD-L1 inhibitor in pivotal Phase III trials for biliary tract cancer
Growth Outlook
  • Pipeline includes multiple candidates in late-stage clinical trials, enhancing potential market entry
  • Strong focus on immunotherapy aligns with industry trends towards personalized cancer treatments
  • Strategic partnerships may accelerate development and commercialization efforts
Financial Highlights
  • Recent quarterly revenue of 271.5 million CNY, showing growth potential
  • Cash and short-term investments total 1.43 billion CNY, providing operational flexibility
  • Current ratio of 4.02 indicates strong liquidity position
Alphamab Oncology's commitment to innovation in cancer therapies positions the company favorably within the biotechnology sector. The ongoing clinical trials and a diverse product pipeline suggest significant growth opportunities. The financial metrics indicate a solid liquidity position, which is crucial for funding research and development activities. As the company continues to advance its clinical programs, it may attract interest from investors looking for exposure to the evolving landscape of cancer treatment.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

498

CEO

Ting Xu, PhD

Website

www.alphamabonc.com

Headquarters

Suzhou, JS 215127, CN

9966 Financials

Key Financial Metrics (TTM)

Gross Margin

76.09%

Operating Margin

-38.04%

Net Income Margin

-33.79%

Return on Equity

-10.27%

Return on Capital

-8.14%

Return on Assets

-8.03%

Earnings Yield

-2.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$6.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

968.51M

Volume

1.36M

Avg. Volume

1.16M

Financials (TTM)

Gross Profit

CN¥1.12B

Operating Income

-CN¥7.66M

EBITDA

CN¥128.12M

Operating Cash Flow

CN¥100.59M

Capital Expenditure

-CN¥54.67M

Free Cash Flow

CN¥45.93M

Cash & ST Invst.

CN¥1.43B

Total Debt

CN¥268.36M

Alphamab Oncology Performance Analysis

Alphamab Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 194,020,41310.2%
20232023-12-31CNY 241,744,83224.6%
20242024-12-31CNY 693,993,250187.1%
20252025-12-31CNY 614,095,091-11.5%
Alphamab Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31168.8%
Q22025-06-30-31.5%
Q42025-12-31-24.0%
Q22026-06-3011.9%
Alphamab Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.40-23.9%
20232023-12-31CNY -0.24-40.1%
20242024-12-31CNY 0.18N/A
20252025-12-31CNY -0.13N/A
Alphamab Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31550.6%
Q22025-06-30-90.5%
Q42025-12-31-750.0%
Q22026-06-3067.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥271.54M

+56.5%

Gross Profit

CN¥212.81M

+49.1%

Gross Margin

78.37%

N/A

Market Cap

HK$6.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$13.01M

N/A

Employees

515

N/A

Net Income

-CN¥40.51M

+9.8%

EBITDA

-CN¥11.84M

+75.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.43B

-1.7%

Total Debt

CN¥268.36M

-17.8%

Accounts Receivable

CN¥30.33M

+130.4%

Inventory

CN¥142.81M

+119.2%

Long Term Debt

CN¥57.74M

-62.2%

Short Term Debt

CN¥210.62M

+21.0%

Return on Assets

-8.03%

N/A

Return on Invested Capital

-11.22%

N/A

Free Cash Flow

-CN¥58.95M

-15.9%

Operating Cash Flow

-CN¥53.03M

-15.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About 9966

What is the current price of Alphamab Oncology?

Alphamab Oncology is trading at HK$6.92 per share.

What is the 52-week range for Alphamab Oncology?

Over the past 52 weeks, Alphamab Oncology has traded between HK$6.23 and HK$15.68.

How much debt does Alphamab Oncology have?

As of the most recent reporting period, Alphamab Oncology reported total debt of CN¥136.97M.

How much cash does Alphamab Oncology have on hand?

Alphamab Oncology reported CN¥288.28M in cash and cash equivalents in its most recent financial results.

What is Alphamab Oncology’s dividend yield?

Alphamab Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services